Cure8 research brief
A systematic review finds risankizumab (an IL-23 inhibitor) effective and generally well tolerated for moderate-to-severe Crohn's disease and ulcerative colitis, including in patients who failed prior biologics. This matters because it supports another treatment option for people with difficult-to-treat IBD.
Adults with moderate-to-severe CD or UC (including biologic-refractory patients); IBD clinicians; IBD researchers.
This article is a systematic review (abstract-level) that pooled studies of risankizumab (an IL-23 inhibitor) for adults with moderate-to-severe Crohn's disease and ulcerative colitis.
The authors report that across 17 studies and 6,602 patients, risankizumab showed favorable clinical remission and endoscopic outcomes, reductions in hospitalizations, and a generally tolerable safety profile with mostly mild-to-moderate adverse events.
The review includes randomized trials and observational studies up to 2025, and highlights benefits in biologic-refractory patients as well as UC and CD populations. The abstract notes rare severe adverse events but emphasizes the need for more data on long-term efficacy and safety.
If you are considering new treatments, this review supports risankizumab as a promising option in moderate-to-severe IBD, particularly for patients who failed prior biologics. Discussing individual suitability, monitoring, and long-term risks with a gastroenterologist is important.
Abstract-level systematic review: pooled randomized and observational studies through 2025. Results suggest benefit but longer-term efficacy and safety remain to be established.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
